Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.
days to go:
Expired
investment:
£388,038
DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.
days to go:
Expired
investment:
£145,000
Elemental is an agricultural food technology company that converts 78% of beef processing waste into sustainable fertiliser. The company claims that its technology can potentially reduce global beef CO2 emissions equivalent to 50 million cattle. Elemental asserts that its technology has been developed through extensive R&D and protected by patents in 60+ countries. The company raised £1.5 million on Crowdcube in late 2019, signed agreements for 14 projects in the UK and Europe using its technology, built a demonstrator plant and agreed to install its technology on commercial terms at 6 UK abattoirs. The company states they will use the investment to operationalise their first plant by December 2021 and grow their business across different verticals.
days to go:
Expired
investment:
£1,395,801
ClearWaste is a price comparison website for waste removal and a provider of enforcement services to councils across the UK. The company argues that the cost to local authorities and taxpayers for cleaning up fly-tipping in England in 2016/17 was £57.7 million and is now thought to exceed £100 million. ClearWaste is on a mission to combat it through its app and web platform utilising reporting and prevention methodologies. The company links consumers with govt-registered waste removers backed by a £1k no-fly-tipping guarantee. ClearWaste argues that the UK waste industry is worth over £6.8 billion and supports more than 103,000 jobs. It aims to be a contender in this segment. ClearWaste has featured in press entities such as BBC, ITV, Channel 5, Sky, Times, and The Guardian. It was also a finalist at the National Recycling Awards 2020. ClearWaste will use the investment to develop its sales and marketing functions and further raise brand awareness.
days to go:
Expired
investment:
£199,599
Plantwork Systems (PWS) is an eco-conscious, technology company providing sustainable and environmentally friendly solutions to the wastewater treatment industry. It is the developer, owner, and provider of a range of proprietary technologies such as TN-REM, NUTREM®, and the deHoxar Spiral Separator. These products aid in nutrient removal, improved filtration, sludge thickening. This leads to wastewater treatment plants recycling more water, reducing their energy requirements, and minimising water scarcity. The company has generated combined revenues of £1.44 million since July 2017. PWS is seeking funding of up to £1 million, at a pre-money valuation of £6 million. It will use the investment to accelerate its growth and bring more innovative products to the market.
days to go:
Expired
investment:
£244,865
Coras is a new technology ticketing platform connecting the world's tickets to people who wish to buy them for any event or activity. The portal has connected multiple ticketing systems into a single system opening up this market to new players for the first time. Coras's marketplace suppliers include West End Theatre tickets, Premier League football and tourist attractions. On the distribution side, it has partnered with Europe's largest airline, Ryanair, Frontier Airlines in the US and Tix.co in Australia. It has also signed other distribution partners in Europe & Asia which it'll announce soon. Ticketing is a $150 billion industry and Coras wants to be a strong contender in this segment. The company will use 85% of investment in software development and build the best product possible that can scale with its distribution and supplier partners.
days to go:
Expired
investment:
£625,760
My Tree has launched a Memorial Park in the UK that enables people to plant a tree with the ashes of their loved one. It is the sole exclusive UK memorial park which offers ashes burial with the planting of a tree. The company is in discussion with DoubleTree Hilton and First Funerals. My Tree has launched its first park five miles outside of Reading and 38 miles from London. The company will use the funds to promote the site, do pre-planting to maximize usage of space and support plans to open more sites by the end of 2020.
days to go:
Expired
investment:
£160,380
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.
days to go:
Expired
investment:
£118,950
